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Hepatic encephalopathy (HE) is defined as a neurological or a neuropsychological 
complication caused by liver disease or portosystemic shunting. The clinical 
spectrum is highly variable ranging from mild neuropsychological disturbances to 
coma [1]. Depending upon the underlying liver disease, HE is classified into 3 types; 
type A, secondary to acute liver failure (ALF); type B, secondary to portosystemic 
shunting and type C, secondary to cirrhosis in the presence or not of shunting [2]. 
The most recent human and animal data confirmed the previously supposed role of 
hyperammonemia, but also outlines the role of associated factors like inflammation in 
the development of HE.  
The main source of ammonia (NH4+) in the portal system has long be thought to be 
intestinal bacterial production explaining the use of non-absorbable disaccharides 
(e.g. lactulose) and non-absorbable antibiotics (e.g. rifaximin) [3]. Recent data shows 
however that the main source is glutamine catabolism by glutaminase in the gut [3]. 
Thus, polymorphisms in the gene coding for glutaminase predicts the development of 
HE in cirrhotic patients [4]. In the systemic circulation, NH4+ is increased due to 
reduced urea cycle enzyme activity that occurs in liver failure and/or portosystemic 
shunting. This increased amount of NH4+ is converted to glutamine in muscle cells 
and in astrocytes, through the action of glutamine synthetase [3,5]. These latter 
abnormalities both explain why sarcopenia represents a factor that makes patients 
susceptible to develop HE in cirrhosis and the development of brain edema patients 
with ALF and cirrhosis. Only, recently directly targeting hyperammonemia by using 
ammonia lowering agents have been proposed (e.g. glycerol-phenylbutyrate, L-
ornithine-L-aspartate). According to its osmotic potential, the acute intracytoplasmic 
increase of glutamine in ALF is responsible for cytotoxic edema affecting the 
astrocytes and for vasogenic edema when the blood-brain barrier (BBB) is altered 
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[3,5]. In cirrhosis, the glutamine increase is gradual and astrocytes respond by 
progressively extruding intracytoplasmic myoinositol and taurine to try and maintain 
osmotic equilibrium. This largely explains why brain edema is rarely present in 
cirrhosis and/or in acute on chronic liver failure (ACLF) [6,7]. In neurons, glutamine is 
deaminated into glutamate, the most important excitatory neurotransmitter in the 
brain, that stimulates neurons [8]. This could account for anxious behaviour, agitation 
or seizures in ALF. In contrast, in cirrhosis, compensatory mechanisms are 
responsible for a decreased expression of both glutamate carriers (GLT-1) and 
glutamate post-synaptic receptors that explains slowing, sleepiness and altered 
consciousness.  
Amino acid imbalance has been hypothesised to participate in HE physiopathology 
[5,9]. Cerebral levels of aromatic aminoacids (AAA) are increased due to altered liver 
function, increased amount of free tryptophan due to hypoalbuminemia but also to 
altered transport through the BBB. As a consequence, there is an imbalance in the 
synthesis of dopamine, norepinephrine, serotonine and in the synthesis of ‘false 
neurotransmitters’, octopamine or tyramine [3,5,8]. Other pathophysiological 
mechanisms such as cerebral energy failure associated to hyperammonemia, altered 
immune responses, reduced blood flow, mitochondrial dysfunction and inhibition of 
alpha-ketoglutarate dehydrogenase, a rate-limiting tricarboxylic acid cycle enzyme 
have been described [9].  
Whereas NH4+ is not directly correlated with neurological status, several studies 
demonstrated a good correlation with the presence of systemic inflammatory 
response syndrome (SIRS) and the blood amount of TNF-alpha or IL-6 [10]. Sepsis 
and systemic inflammation are a hallmark of the severity of cirrhosis and infection is 
a classical triggering event of HE [11]. Outside the field of cirrhosis, encephalopathy 
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related to sepsis has been described. Modification of the intestinal microbiota is 
emerging as a major factor associated with HE [5,12]. It modulation has been 
proposed to explain the effect of lactulose and rifaximin with conflicting results. More 
recently, fecal transplantation has been proposed as a therapeutic strategy in HE. 
Liver failure is associated with altered intestinal barrier function, which is responsible 
for bacterial translocation and activation of innate immune system. Nevertheless, this 
innate immune response is altered in liver failure as defined by altered neutrophil 
phagocytic capacity, reduced reticuloendothelial system and reduced hepatic 
synthesis of antimicrobial proteins [13]. ACLF is characterised by upregulation of 
proinflammatory cytokines (IL-1, IL-6, IL-17, TNF-alpha, IFN-gamma) compared to 
stable cirrhotic patients [14]. In the brain of HE patients, astrocytes and microglial 
cells respond to systemic inflammation by producing IL-1beta and IL-6 that stimulate 
adhesion of neutrophils and their trans-endothelial migration through the BBB, the 
release of chemokines, proteases and reactive oxygene species [5]. As a result, 
microglial cells present an activated phenotype. Current data suggest that the brain 
of patients with cirrhosis are sensitised to the effect of systemic inflammation and 
infection. Therefore, prompt treatment of any infection is an important therapeutic 
intervention. Noteworthy, anti-inflammatory treatments, i.e. indomethacin or 
ibuprofen, blocking microglial activation, are able to prevent both neurocognitive 
symptoms and brain edema in several animal models of HE [10].  
Apart from hyperammonemia and inflammation, other factors are suspected to be 
involved in the physiopathology of HE. Thus, neurotransmission is largely impaired in 
HE, either as a consequence, as previously discussed for both glutamate, dopamine 
and serotonin, or as a cause, increased intracerebral levels of benzodiazepine-like 
compounds or neurosteroids that end in an increased gamma-amino-butyric acid 
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(GABA) tone [8]. The presence of benzodiazepine-like compounds explains why the 
use of flumazenil had been proposed in the treatment of HE. Due to liver failure, 
several substances have been reported in excess in HE patients: phenols, 
mercaptans, short chain fatty acids, manganese or bile acids [9].  
Using metabolomics, we recently showed that HE patients displayed several drugs, 
especially antimicrobial agents (eg. metronidazole, fluconazole or betalactamins), in 
their CSF [9]. This is in line with clinical studies that could link neurological symptoms 
with beta-lactams or proton pumps inhibitor intake in cirrhotic patients [15]. 
Remarkably, these drugs are all substrates of ATP-binding cassette (ABC)-
transporters expressed on the BBB and responsible for efflux of several drugs 
outside the brain. We recently showed in HE animal models that ABC-transporters 
expression was altered compared to cirrhotic animals without HE (personal data). 
These data suggest that some neurological abnormalities could be related to drug-
induced encephalopathy. Nevertheless, recent animal data showed that both bilirubin 
and bile acids exposure could induce a down-regulation of P-glycoprotein (P-gp), the 
main ABC-transporter, on the BBB and that this decreased expression could favour 
cerebral GABA concentrations. Administration of these drugs should be carefully 
considered in cirrhotic patients and considered in the differential diagnosis of brain 
dysfunction. 
 
Recent progress in cellular biology and immunology has modified our concept of HE 
physiopathology and will, in the future, provide new treatments. 
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Figure: Hepatic encephalopathy physiopathology hallmarks: ammonia (1, 2, 3 
and 4) and inflammation (a, b and c) are the main actors. 
 
1, As opposed to previous theories, the main source of NH4+ in the portal circulation is intestinal 
catabolism of glutamine; 2, Once increased in the portal circulation, NH4+ increases in the systemic 
circulation due to liver failure (reduced activity of urea cycle enzymes) and/or portosystemic shunting; 
3, In the case of liver failure, NH4+ detoxification into glutamine through glutamine synthetase is only 
possible in the muscle cells and the astrocytes. In muscles cells, this reaction needs the use of BCAA, 
which are decreased in cirrhosis. In astrocytes, the rapid increase in glutamine explains the 
occurrence of cytotoxic edema seen in the astrocytes through its osmotic potential. In more 
progressive disease, osmotic components, myoinositol and taurine, are extruded outside the 
cytoplasm to counterbalance the glutamine increase to try and prevent astrocytic edema. 4, The 
observed neuronal effects may vary; hyperstimulation and seizures may be due to accumulation of 
glutamate in the synaptic cleft; coma due to increased GABA in the brain; psychomotor disturbance 
due to other neurotransmitters. 
a, Due to modification of the gut microbiota, intestinal barrier function is altered and bacterial 
translocation abnormally increased. This leads to an increase of pro-inflammatory cytokines in the 
portal circulation; b, Acquired cellular immune depression related to liver disease further favours 
proinflammatory cytokine production; c, Systemic inflammation induces an alteration of blood-brain 
barrier permeability, and pro-inflammatory cytokines, especially IL-1 and IL-6, activate both 
astrocytes and microglial cells. Several of these steps can be worsened by hyperammonemia, as 
shown in vitro on cell cultures or in vivo in animal models. 
Other abnormalities have been described in HE physiopathology. Among them, accumulation of 
several substances such as increased AAA levels, increased GABA tone through benzodiazepine-like 
components or neurosteroids. Recent studies implicated drug accumulation in the cerebrospinal fluid 
as contributing to the physiopathology of HE. 
Different treatment strategies that has been validated or proposed in the treatment of HE are 
represented preceded by the pill icon in the figure. 
 
Abbreviations: AAA, aromatic amino acids; ABC transporters, ATP-binding cassette transporters; BCAA, branched-chain amino 
acids; CD, cluster of differentiation; GABA, gamma-amino-butyric acid ; GLN, glutamine; HE, hepatic encephalopathy; HLA-DR, 
human leukocyte antigen – antigen D related; IFN, interferon; IL, interleukine; LPS, lipopolysaccharide; NH4+, ammonia; TNF, 
tumor necrosis factor. 
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